Survivin Peptide Vaccine
Anaplastic Oligoastrocytoma
Explore 4 assets in Anaplastic Oligoastrocytoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
vaccine
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01250470CT.gov Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Oligoastrocytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Survivin Peptide Vaccine (this asset) | Roswell Park Cancer Institute | P1 | CC · 47 |
| Α-Ifn | Sun Yat-sen University | P3 | B |
| Β-Elemene | Sun Yat-sen University | P3 | B |
| Camustine | Shandong Lanjin Pharmaceuticals Co.,Ltd | P3 | B |
| Resiquimod | Jonsson Comprehensive Cancer Center | P2 | B |
| Tandutinib | National Cancer Institute (NCI) | P2 | B |
| Carboplatin | National Cancer Institute (NCI) | P2 | B |
| Dendritic Cells Pulsed With Tumor Lysate | Jonsson Comprehensive Cancer Center | P2 | B |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine | Jonsson Comprehensive Cancer Center | P2 | B |
+28 more in the Anaplastic Oligoastrocytoma cohort
Other indications for Survivin Peptide Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Giant Cell Glioblastoma | — | P1 | CC · 47 |
| Anaplastic Oligodendroglioma | — | P1 | CC · 47 |
| Mixed Glioma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Survivin Peptide Vaccine in Anaplastic Oligoastrocytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/survivin-peptide-vaccine-anaplastic-oligoastrocytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →